— Presentations Will Include Edasalonexent and Rare Disease Pipeline
—
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, announced today that it will be hosting its
first Investor Day and simultaneous webcast on November 17, 2016 from
8:30am to 11:30am ET in New York City. The Company will discuss
corporate strategy and its pipeline in rare diseases, including
presentations on edasalonexent (CAT-1004) and Duchenne muscular
dystrophy (DMD) by external Duchenne experts and Catabasis leadership
team members.
Presenting at the event:
Key opinion leaders:
-
Craig M. McDonald, M.D., UC Davis NeuroNEXT Program Director, University
of California -
H. Lee Sweeney, Ph.D., UF Myology Institute Director,
University of Florida
Catabasis leadership team:
-
Joanne M. Donovan, M.D., Ph.D., Chief Medical Officer and Senior
Vice President, Clinical Development - Jill C. Milne, Ph.D., Co-Founder and Chief Executive Officer
- Rick Modi, Chief Business Officer
- Andrew Nichols, Ph.D., Chief Scientific Officer
The Investor Day is open to members of the professional investment
community. To register, please email CATB@macbiocom.com.
Webcast Information:
Interested parties may access the live
webcast of the event at http://edge.media-server.com/m/p/7h9t7i6s
or via the investor section of the Catabasis website, www.catabasis.com.
Please connect to the Catabasis website several minutes prior to the
start of the broadcast to ensure adequate time for any software download
that may be necessary. The webcast will be archived for 90 days.
About Catabasis
At Catabasis Pharmaceuticals, our mission is
to bring hope and life-changing therapies to patients and their
families. Our SMART (Safely Metabolized And Rationally Targeted) linker
drug discovery platform enables us to engineer molecules that
simultaneously modulate multiple targets in a disease. We are applying
our SMART linker platform to build an internal pipeline of product
candidates for rare diseases and plan to pursue partnerships to develop
additional product candidates. For more information on the Company’s
drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.
Image may be NSFW.
Clik here to view.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161103005062/en/
Source: Catabasis Pharmaceuticals, Inc.
Cet article Catabasis Pharmaceuticals to Host Investor Day in New York City on
November 17 est apparu en premier sur EEI-BIOTECHFINANCES.